The Impact of Vascular Access Complications in Patients Undergoing Transcatheter Aortic Valve Replacement
Catheterization and Cardiovascular Interventions · 2026-06 · 107 (7) · 2373-2382
DOI: 10.1002/ccd.70560 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Catheterization and Cardiovascular Interventions, online erschienen am 12.04.2026. Verfasst von Tomaz Mesar und 10 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Cardiac Catheterization, Catheterization, Peripheral, Femoral Artery. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background
Vascular complications remain a significant concern in transfemoral transcatheter aortic valve replacement (TAVR).
Aims
Determine the incidence of vascular complications following TAVR and evaluate their impact on short‐ and long‐term clinical outcomes.
Methods
We conducted a retrospective observational analysis of patients undergoing transfemoral TAVR at a single institution. Patients were stratified into three groups: Group 0 (no perioperative complications), Group 1 (vascular complications), and Group 2 (non‐vascular complications). The primary outcome was early‐ and late‐mortality. Propensity score matching was performed to compare outcomes between Group 0 and Group 1.
Results
Among 5230 patients, 4391 (84.0%) were in Group 0, 154 (2.9%) in Group 1, and 685 (13.1%) in Group 2. In Group 1, 36.4% experienced intraoperative bleeding requiring intervention, 27.3% had intraoperative limb ischemia or dissection, and 16.2% required postoperative takeback for limb ischemia. In‐hospital mortality was 12/154 (7.8%) in Group 1, compared with 7/4391 (0.2%) in Group 0 and 45/685 (6.6%) in Group 2 ( p < 0.001). Thirty‐day mortality was 16/154 (10.4%) in Group 1 versus 117/4391 (2.7%) in Group 0 and 70/685 (10.2%) in Group 2 ( p < 0.001). Propensity‐matched analysis showed Group 1 had fourfold higher 30‐day mortality (OR 4.02, 95% CI 1.98–8.18, p < 0.001). One‐year mortality was 29/148 (19.6%) for Group 1 compared with 72/592 (12.2%) for Group 0, with 5‐year survival similar between groups (Group 1: 51.1%, Group 0: 50.9%, log‐rank p = 0.214), while unmatched Group 2 had 43.1% 5‐year survival.
Conclusion
While vascular complications after TAVR are uncommon, they are linked to substantially worse early outcomes, whereas long‐term survival among patients who survive the initial postoperative period remains comparable, emphasizing the critical impact during the early phase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UPMC Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Xander Jacquemyn, Catalin Toma
Zitieren
APA
Mesar, T., Jackson, A., Chachati, G., Jacquemyn, X., Ahmad, D., Kliner, D., Serna-Gallegos, D., Toma, C., West, D., Makani, A., & Sultan, I. (2026). The Impact of Vascular Access Complications in Patients Undergoing Transcatheter Aortic Valve Replacement. Catheterization and Cardiovascular Interventions, 107(7), 2373-2382. https://doi.org/10.1002/ccd.70560
Vancouver
Mesar T, Jackson A, Chachati G, Jacquemyn X, Ahmad D, Kliner D, et al. The Impact of Vascular Access Complications in Patients Undergoing Transcatheter Aortic Valve Replacement. Catheterization and Cardiovascular Interventions. 2026;107(7):2373-2382. doi:10.1002/ccd.70560
BibTeX
@article{Mesar2026,
author = {Mesar, Tomaz and Jackson, Ariana and Chachati, George and Jacquemyn, Xander and Ahmad, Danial and Kliner, Dustin and Serna-Gallegos, Derek and Toma, Catalin and West, David and Makani, Amber and Sultan, Ibrahim},
title = {The Impact of Vascular Access Complications in Patients Undergoing Transcatheter Aortic Valve Replacement},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
volume = {107},
number = {7},
pages = {2373--2382},
doi = {10.1002/ccd.70560}
}
EUVIMED